Skip to main content
. 2020 Feb 13;18:76. doi: 10.1186/s12967-020-02232-z

Table 1.

Patient demographics and baseline characteristics

Items Tianzhi
(n = 232)
Donepezil
(n = 233)
Placebo
(n = 55)
Gender, male/female 154/78 149/84 35/20
Race, han/other 226/6 233/0 54/1
Age, mean (SD) 64.72 (9.18) 64.31 (9.99) 63.95 (9.15)
Education
 Primary school, N (%) 82 (35.34) 85 (36.48) 23 (41.82)
 Middle school and above, N (%) 150 (64.66) 148 (63.52) 32 (58.18)
Smoking history, (yes/no) 97/134 96/136 24/31
Drinking history, (yes/no) 80/151 69/163 18/37
Neuropsychological score, Mean (SD)
 VADAS-cog 52.64 (10.59) 53.29 (10.17) 52.22 (11.36)
 MMSE 20.56 (3.36) 20.56 (3.24) 20.51 (2.97)
 TMT-A 112.05 (41.03) 113.26 (45.52) 124.69 (47.46)
 TMT-B 208.42 (87.42) 209.42 (88.92) 235.83 (71.05)
 ADL 15.15 (9.62) 14.66 (9.76) 14.87 (8.81)
 CDT 2.48 (1.21) 2.53 (1.20) 2.35 (1.27)
 NPI 5.31 (5.52) 5.35 (4.91) 5.40 (5.51)

VADAS-cog vascular dementia assessment scale-cognitive subscale, NPI Neuropsychiatric Inventory, MMSE mini-mental state examination, ADL activity of daily living scale, CDT clock drawing test, TMT-A trail making test part A, TMT-B trail making test part B